Cargando…

Management of hepatitis B virus reactivation due to treatment of COVID-19

The world has made significant progress in developing novel treatments for COVID-19 since the pandemic began. Some treatments target the patient’s dysregulated inflammatory response during COVID-19 infection and may cause hepatitis B reactivation (HBVr) in patients with current or past hepatitis B v...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yip, Terry Cheuk-Fung, Gill, Madeleine, Wong, Grace Lai-Hung, Liu, Ken
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer India 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8889512/ https://www.ncbi.nlm.nih.gov/pubmed/35235148 http://dx.doi.org/10.1007/s12072-022-10306-x

Ejemplares similares

Moving toward hepatitis B virus functional cure - the impact of on-treatment kinetics of serum viral markers
por: Liang, Lilian Yan, et al.
Publicado: (2023)

Secondary prevention for hepatocellular carcinoma in patients with chronic hepatitis B: are all the nucleos(t)ide analogues the same?
por: Yip, Terry Cheuk-Fung, et al.
Publicado: (2020)

Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact
por: Yip, Terry Cheuk-Fung, et al.
Publicado: (2021)

Alanine Aminotransferase Level: The Road to Normal in 2021
por: Yip, Terry Cheuk‐Fung, et al.
Publicado: (2021)

Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog
por: Hui, Vicki Wing-Ki, et al.
Publicado: (2021)

Reply
por: Wong, Grace Lai-Hung, et al.
Publicado: (2023)

Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B
por: Liang, Lilian Yan, et al.
Publicado: (2021)

Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir
por: Wong, Grace Lai-Hung, et al.
Publicado: (2022)

U-shaped relationship between urea level and hepatic decompensation in chronic liver diseases
por: Lin, Huapeng, et al.
Publicado: (2022)

Baveno VII criteria for recompensation predict transplant-free survival in patients with hepatitis B-related decompensated cirrhosis
por: Hui, Vicki Wing-Ki, et al.
Publicado: (2023)

Unmet need in chronic hepatitis B management
por: Liang, Lilian Yan, et al.
Publicado: (2019)

Association of metformin use on metabolic acidosis in diabetic patients with chronic hepatitis B‐related cirrhosis and renal impairment
por: Yip, Terry Cheuk‐Fung, et al.
Publicado: (2021)

Sequence Variations of Full-Length Hepatitis B Virus Genomes in Chinese Patients with HBsAg-Negative Hepatitis B Infection
por: Huang, Fung-Yu, et al.
Publicado: (2014)

Two different types of COVID-19 vaccines and serial liver biochemistries
por: Wong, Grace Lai-Hung, et al.
Publicado: (2022)

Three COVID-19 medications-remdesivir, molnupiravir and ritonavir-boosted nirmatrelvir-and serial liver biochemistries in 22, 456 subjects
por: Wong, Grace Lai-Hung, et al.
Publicado: (2022)

Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend
por: Wong, Grace Lai-Hung
Publicado: (2018)

Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future
por: Yip, Terry Cheuk-Fung, et al.
Publicado: (2023)

Minimal Risk of Drug-Induced Liver Injury With Molnupiravir and Ritonavir-Boosted Nirmatrelvir
por: Wong, Grace Lai-Hung, et al.
Publicado: (2023)

Clinical outcomes of patients with acute lymphoblastic leukemia receiving the hyper-CVAD regimen and assessment of the risk of hepatitis flares due to hepatitis B virus reactivation after chemotherapy
por: Law, Man Fai, et al.
Publicado: (2021)

Management of Hepatitis B Virus Reactivation in Malignant Lymphoma Prior to Immunosuppressive Treatment
por: Tsai, Yu-Fen, et al.
Publicado: (2021)

Hepatitis B virus reactivation in seronegative occult hepatitis B patient receiving ibrutinib therapy
por: Lam, Lok-Ka, et al.
Publicado: (2023)

Hepatitis B Virus Reactivation under Treatment with Nilotinib
por: Temel, Tuncer, et al.
Publicado: (2015)

358. HIV Infection and the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Virus (HBV) Co-infection: a Propensity Score-matched Cohort Study
por: Lui, Grace, et al.
Publicado: (2019)

Fulminant Liver Failure due to Hepatitis B Reactivation During Treatment With Tocilizumab
por: Sonneveld, Milan J., et al.
Publicado: (2019)

The truth of the matter: will immune-tolerant chronic hepatitis B patients benefit from antiviral treatment?
por: Jeng, Wen-Juei, et al.
Publicado: (2023)

Pattern and impact of hepatic adverse events encountered during immune checkpoint inhibitors – A territory‐wide cohort study
por: Chan, Stephen Lam, et al.
Publicado: (2020)

Hepatitis B Virus Reactivation Following Treatment of HNSCC With Cisplatin
por: Crosby, James, et al.
Publicado: (2022)

Atypical presentation of Good syndrome: acute hepatitis from hepatitis B virus reactivation
por: Lai, Yi Wye, et al.
Publicado: (2020)

Novel machine learning models outperform risk scores in predicting hepatocellular carcinoma in patients with chronic viral hepatitis
por: Wong, Grace Lai-Hung, et al.
Publicado: (2022)

Baveno VII Criteria Is an Accurate Risk Stratification Tool to Predict High-Risk Varices Requiring Intervention and Hepatic Events in Patients with Advanced Hepatocellular Carcinoma
por: Wu, Claudia Wing-Kwan, et al.
Publicado: (2023)

Clinical Outcomes Following Treatment for COVID-19 With Nirmatrelvir/Ritonavir and Molnupiravir Among Patients Living in Nursing Homes
por: Ma, Bosco Hon-Ming, et al.
Publicado: (2023)

Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitis
por: Inada, Kento, et al.
Publicado: (2021)

The use of transient elastography in the management of chronic hepatitis B
por: Fung, James, et al.
Publicado: (2011)

Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations
por: Koutsianas, Christos, et al.
Publicado: (2020)

Evolutionary Changes of Hepatitis B Virus Pre-S Mutations Prior to Development of Hepatocellular Carcinoma
por: Zhang, An-Ye, et al.
Publicado: (2015)

Hepatitis B virus reactivation in rheumatoid arthritis
por: Wu, Ya-Li, et al.
Publicado: (2022)

Serum hepatitis B surface antigen (HBsAg) kinetics in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B
por: Seto, Wai-Kay, et al.
Publicado: (2012)

High Hepatitis B Surface Antigen Levels Predict Insignificant Fibrosis in Hepatitis B e Antigen Positive Chronic Hepatitis B
por: Seto, Wai-Kay, et al.
Publicado: (2012)

Risk of Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Tocilizumab-Containing Treatment
por: Kuo, Meng Hsuan, et al.
Publicado: (2021)

SARS-CoV-2 Viral Persistence Based on Cycle Threshold Value and Liver Injury in Patients With COVID-19
por: Wong, Grace Lai-Hung, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_29suo4quvn673t4b35hf3d4arn